These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36088128)

  • 1. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease.
    Pampín-Sánchez R; Martínez-Mugica-Barbosa C; Fonseca-Aizpuru EM; Barbazán-Vázquez FJ; Fernández-González B; Buznego-Súárez L
    Med Clin (Barc); 2023 Feb; 160(3):113-117. PubMed ID: 36088128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
    Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
    Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for thyroid eye disease.
    Hamed Azzam S; Kang S; Salvi M; Ezra DG
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012984. PubMed ID: 30480323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
    Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
    Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.
    Lee C; Park JW; Kim YD; Woo KI
    Int Ophthalmol; 2024 Apr; 44(1):179. PubMed ID: 38622479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.
    Maldiney T; Deschasse C; Bielefeld P
    Ocul Immunol Inflamm; 2020; 28(2):281-284. PubMed ID: 30457413
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to tocilizumab treatment in Graves' ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography.
    de-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Troyano-Rivas J; Niño-Rueda C; Romo-López Á; Gómez-de-Liaño R
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Aug; 93(8):386-391. PubMed ID: 29937157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
    Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
    Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 46-Year-Old Woman with a 4-Year History of Graves Disease, with Severe Corticosteroid-Unresponsive Thyroid Eye Disease, Successfully Treated with Tocilizumab.
    Almazrouei O; Alalawi F; Albrashdi S; Alsharqi H; Alsaadi A; Hammad M; Sabri A; Eatamadi H
    Am J Case Rep; 2023 Feb; 24():e938487. PubMed ID: 36788719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orbital radiation therapy for Graves' ophthalmopathy: measuring clinical efficacy and impact.
    Hahn E; Laperriere N; Millar BA; Oestreicher J; McGowan H; Krema H; Gill H; DeAngelis D; Hurwitz J; Tucker N; Simpson R; Chung C
    Pract Radiat Oncol; 2014; 4(4):233-9. PubMed ID: 25012831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
    Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
    Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
    Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
    Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study.
    Dorado Cortez O; Grivet D; Perrillat N; Gain P; Thuret G
    Orbit; 2023 Aug; 42(4):411-417. PubMed ID: 36065465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
    Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
    Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab.
    Rymuza J; Kuś A; Białas-Niedziela D; Turczyńska M; Kęcik D; Bednarczuk T
    Endokrynol Pol; 2024; 75(1):117-118. PubMed ID: 38497401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.